engleski

P53 and BCL-2 expression in extrahepatic bile duct carcinomas

The aim of the present study was to analyse the expression p53 and bcl-2 in the extrahepatic bilc duct carcinomas (EHBDC). We analysed tumour 13 patients with EHBDC's diagnosed at "Sestre milosrdnice" University Hospital in the 1990-1996 period. There were 10 female and 3 male patients ranging in age from 56-94 years. In 8 patients only palliative treatments was performed. Five patients underwent surgical resection. Histologic analysis revealed adenocarcinoma in all cases. Formalin fixed, paraffin embedded tumour tissue of these five patients was cut at 5 mm, deparaffinized, and stained with an antibody to p53 and bcl-2 (Dako, Denmark). Alkaline phosphatase/antialkaline phosphatase method was used. The intensity of immunostaining was graded semiquantitively and designated with (-) for no staining, (+) for 10% positive cells, (++) for 25% positive cells and (+++) for more than 25% positive cells. Histopathologic examination showed p53 expression in all cases: in 2 tumours the reaction was weakly positive (+), and in 3 tumours strongly positive (+++). We found weakly positive immunostaining for bcl-2 in 2 tumours, moderately positive in one tumour and strongly positive in 2 tumours (Table). We conclude that EHBDC's are uncommon tumours and the results of tretment at present are rather poor. It seems that p53 and bcl-2 are present EHBDC indicating their possible role in the development of these tumours. Assessmrnt of clinical and pathological impact of these genes on EHBDC requires evaluation in larger studies.

P53; BCL-2; extrahepatic bile duct carcinomas

nije evidentirano